Spasmodic dystonia
disease diseaseOn this page
Also known as abductor spasmodic dysphoniaadductor spasmodic dysphonialaryngeal dyskinesialaryngeal dystoniamixed spasmodic dysphonia (type)spasmodic dysphoniaspastic dysphonia
Summary
Spasmodic dystonia (MONDO:0000485) is a disease and 40 clinical trials. Top therapeutic interventions include oxybate, pyridostigmine, and daxibotulinumtoxina. A subtype of focal dystonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 40
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | spasmodic dystonia |
| Mondo ID | MONDO:0000485 |
| MeSH | D055154 |
| Orphanet | 93961 |
| DOID | DOID:0050844 |
| SNOMED CT | 3331000119108 |
| UMLS | C1963946 |
| MedGen | 409603 |
| GARD | 0027260 |
| Is cancer (heuristic) | no |
Also known as: abductor spasmodic dysphonia · adductor spasmodic dysphonia · laryngeal dyskinesia · laryngeal dystonia · mixed spasmodic dysphonia (type) · spasmodic dysphonia · spastic dysphonia
Disease family
This is a subtype of focal dystonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › focal dystonia › spasmodic dystonia
Related subtypes (11): anismus, cervical dystonia, focal hand dystonia, oculogyric crisis, craniofacial dystonia, X-linked dystonia-parkinsonism, torsion dystonia 7, benign essential blepharospasm, dystonia 23, oromandibular dystonia, dystonia, focal, task-specific
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Lidocaine | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 40.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE2/PHASE3 | 3 |
| PHASE2 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE1 | 2 |
| PHASE4 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05110417 | PHASE4 | UNKNOWN | Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine |
| NCT02528006 | PHASE2/PHASE3 | COMPLETED | Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges |
| NCT03292458 | PHASE2/PHASE3 | COMPLETED | Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor |
| NCT04648891 | PHASE2/PHASE3 | COMPLETED | Spasmodic Dysphonia Pain |
| NCT05892770 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia |
| NCT01961297 | PHASE2 | COMPLETED | Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response |
| NCT04938154 | PHASE2 | UNKNOWN | A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia |
| NCT05158166 | PHASE1/PHASE2 | COMPLETED | DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia |
| NCT05467228 | PHASE2 | WITHDRAWN | Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia |
| NCT06111027 | PHASE1/PHASE2 | COMPLETED | Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia |
| NCT07041203 | PHASE1 | NOT_YET_RECRUITING | Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor |
| NCT00015795 | PHASE1 | COMPLETED | Study of Air Stream in Voice Production |
| NCT05216770 | EARLY_PHASE1 | RECRUITING | Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor |
| NCT03042962 | Not specified | RECRUITING | Brain Networks in Dystonia |
| NCT03042975 | Not specified | RECRUITING | Imaging Genetics of Laryngeal Dystonia |
| NCT04421365 | Not specified | RECRUITING | Brain-Computer Interfaces in Laryngeal Dystonia |
| NCT05095740 | Not specified | RECRUITING | Effects of Neuromodulation in Laryngeal Dystonia |
| NCT05150093 | Not specified | RECRUITING | Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor |
| NCT05150106 | Not specified | RECRUITING | Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor |
| NCT05245942 | Not specified | ACTIVE_NOT_RECRUITING | Monitoring of the Safety and the Performance of the Endoscopic Cap Electrode (ECE50) |
| NCT05506085 | Not specified | RECRUITING | Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application |
| NCT06078527 | Not specified | NOT_YET_RECRUITING | Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort |
| NCT06561334 | Not specified | ACTIVE_NOT_RECRUITING | Spasmodic Dysphonia Interviews |
| NCT06830174 | Not specified | RECRUITING | tDCS for Laryngeal Dystonia |
| NCT07443891 | Not specified | RECRUITING | Brain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia |
| NCT00001552 | Not specified | COMPLETED | Characteristics of Idiopathic Familial Voice Disorders |
| NCT00001922 | Not specified | COMPLETED | Sensory Function in Idiopathic Voice Disorders |
| NCT00118586 | Not specified | COMPLETED | Neuropathology of Spasmodic Dysphonia |
| NCT00713414 | Not specified | COMPLETED | Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia |
| NCT00895063 | Not specified | TERMINATED | Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia |
| NCT02061943 | Not specified | WITHDRAWN | Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change |
| NCT02558634 | Not specified | COMPLETED | Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial |
| NCT02957942 | Not specified | COMPLETED | rTMS in Spasmodic Dysphonia |
| NCT03129087 | Not specified | UNKNOWN | The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia |
| NCT03349086 | Not specified | COMPLETED | Effects of Vocal Exercises for Spasmodic Dysphonia |
| NCT03746509 | Not specified | COMPLETED | Laryngeal Vibration for Spasmodic Dysphonia |
| NCT05158179 | Not specified | COMPLETED | Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia |
| NCT05580302 | Not specified | UNKNOWN | Cortical Silent Period in Laryngeal Dystonia |
| NCT06402214 | Not specified | UNKNOWN | The ‘Lombard Effect’ in Patients Affected by Adductor Laryngeal Dystonia |
| NCT06767215 | Not specified | COMPLETED | Dysphonia Pain Perception Following Botulinum Toxin Injections |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OXYBATE | 4 | 9 |
| PYRIDOSTIGMINE | 4 | 2 |
| DAXIBOTULINUMTOXINA | 4 | 1 |
| LIDOCAINE | 4 | 1 |
Related Atlas pages
- Drugs: Oxybate, Pyridostigmine, Daxibotulinumtoxina, Lidocaine